Reproval 5% Small Animal Injection for Dogs and Cats

Main information

  • Trade name:
  • Reproval 5% Small Animal Injection for Dogs and Cats
  • Pharmaceutical form:
  • Solution for injection
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Reproval 5% Small Animal Injection for Dogs and Cats
    Italy
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • carprofen
  • Therapeutic area:
  • Cats, Dogs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0328/001
  • Authorization date:
  • 29-10-2008
  • EU code:
  • UK/V/0328/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Revised:November2012

AN:00800/2012

Page1of6

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Reproval50mg/mlSolutionforInjectionforDogsandCats(RMS)

Norocarp50mg/mlSolutionforInjectionforDogsandCats(allCMSexcept

France,Germany,SwedenandDenmark)

Carprieve50mg/mlSolutionforInjectionforDogsandCats(Franceand

Germany)

Norocarpvet.50mg/mlSolutionforInjectionforDogsandCats(Sweden)

Norodylvet.50mg/mlSolutionforInjectionforDogsandCats(Denmark)

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachmlcontains:

Activesubstance:

Carprofen 50mg

Excipients:

BenzylAlcohol 10mg

SodiumFormaldehydeSulphoxylate 2.5mg

Forafulllistofexcipients,seesection6.1

3. PHARMACEUTICALFORM

SolutionforInjection

Aclearcolourlesstopaleyellowsolution.

4. CLINICALPARTICULARS

4.1 TargetSpecies

DogsandCats

4.2 IndicationsforUse,SpecifyingtheTargetSpecies

Dogs:Forthecontrolofpost-operativepainandinflammationfollowing

orthopaedicandsofttissue(includingintra-ocular)surgery.

Cats:Forthecontrolofpostoperativepainfollowingovariohysterectomy

andsofttissuesurgery.

Revised:November2012

AN:00800/2012

Page2of6

4.3 Contraindications

Donotuseinanimalssufferingfromcardiac,hepaticorrenaldiseaseor

gastrointestinalproblems,wherethereisapossibilityofgastrointestinal

ulcerationorbleeding,orhypersensitivitytocarprofenoranyotherNSAIDs

oranyexcipientsofthisproduct.AswithotherNSAIDsthereisariskof

rarerenaloridiosyncratichepaticadverseevents.

Donotuseaftersurgerywhichwasassociatedwithconsiderablebloodloss.

Donotuseincatsonrepeatedoccasions.

Donotuseincatslessthan5monthsofage.

Donotuseindogslessthan10weeksofage.

SeealsoSection4.7andSection4.8

4.4 SpecialWarningsforEachTargetSpecies

Inthecat,duetothelongerhalf-life,andnarrowertherapeuticindex,

particularcareshouldbetakennottoexceedtherecommendeddoseand

theuseofagraduated1mlsyringeisrecommendedtomeasurethedose

accurately.

4.5 SpecialPrecautionsforUse

i. SpecialPrecautionsforUseinAnimals

Donotexceedtherecommendeddoseordurationoftreatment

especiallyinthecat.

Useinageddogsandcats,mayinvolveadditionalrisk.Ifsuchuse

cannotbeavoided,suchanimalsmayrequireareduceddosageand

carefulclinicalmanagement.

Avoiduseinanydehydrated,hypovolaemicorhypotensiveanimal,

asthereisapotentialriskofincreasedrenaltoxicity.

NSAIDscancauseinhibitionofphagocytosisandhenceinthe

treatmentofinflammatoryconditionsassociatedwithbacterial

infection,appropriateconcurrentantimicrobialtherapyshouldbe

instigated.

ii. Specialprecautionstobetakenbythepersonadministeringthe

veterinarymedicinalproducttoanimals

Careshouldbetakenwhenhandlingtheproducttoavoidaccidental

self-injectionandskincontact.Ifskincontactoccurswashany

productfromtheskinimmediately.Washhandsafteruse.

Revised:November2012

AN:00800/2012

Page3of6

4.6 AdverseReactions(FrequencyandSeriousness)

TypicalundesirableeffectsassociatedwithNSAIDssuchasvomiting,soft

faeces/diarrhea,faecaloccultblood,lossofappetiteandlethargyhavebeen

reported.Theseadversereactionsoccurgenerallywithinthefirsttreatment

weekandareinmostcasestransientanddisappearfollowingterminationof

thetreatmentbutinveryrarecasesmaybeseriousorfatal.

Ifadversereactionsoccur,useoftheproductshouldbestoppedandthe

adviceofaveterinarianshouldbesought.

AswithotherNSAIDsthereisariskofrarerenaloridiosyncratichepatic

adverseevents.

Occasionallyreactionsattheinjectionsitemaybeobservedfollowing

subcutaneousinjection.

4.7 UseDuringPregnancy,LactationorLay

Laboratorystudiesinlaboratoryanimals(rat,rabbit)haveshownevidence

offoetotoxiceffectsofcarprofenatdosesclosetothetherapeuticdose.

Thesafetyoftheveterinarymedicinalproducthasnotbeenestablishedduring

pregnancyandlactation.Donotuseindogsorcatsduringpregnancyor

lactation.

4.8 InteractionwithotherMedicinalProductsandOtherFormsofInteraction

DonotadministerotherNSAIDsandglucocorticoidsconcurrentlyorwithin

24hoursoftheadministrationoftheproduct.Carprofenishighlyboundto

plasmaproteinsandmaycompetewithotherhighlybounddrugs,whichcan

leadtotoxiceffects.

Concurrentadministrationofpotentialnephrotoxicdrugsshouldbeavoided.

4.9 AmountstobeAdministeredandAdministration

Dogs:Inthedog,therecommendeddosageis4mg/kg(1ml/12.5kg)

bodyweight,byintravenousorsubcutaneousinjection,bestgiven

pre-operatively,eitheratthetimeofpremedicationorinductionof

anaesthesia.

Clinicaltrialevidenceindogssuggeststhatonlyasingledoseof

carprofenisrequiredinthefirst24hoursoftheinitialdose,however

iffurtheranalgesiaisrequiredpostsurgerywithinthis24hourperiod,

asinglehalf-dose(2mg/kg)ofcarprofenmaybegiventodogsas

necessary.

Revised:November2012

AN:00800/2012

Page4of6

Toextendanalgesicandanti-inflammatorycoverpost-operatively,

parenteraltherapymaybefollowedwithCarprofenTabletsat4

mg/kg/dayforupto5days.

Cats:Inthecat,therecommendeddosageis4mg/kg(0.24ml/3kg)

bodyweightasasingledosebyintravenousinjection,bestgivenpre-

operativelyatthetimeofanaesthesia.SeealsoSection4.4.

Forperi-operativeuseitisrecommendedtoadministertheproductat

least30minutesbeforeanaesthesia.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Thereisnospecificantidoteforcarprofenoverdosagebutgeneral

supportivetherapyasappliedtoclinicaloverdosagewithNSAIDsshouldbe

applied.

4.11WithdrawalPeriod(s)

Notapplicable

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:Antiflammatoryandantirheumaticproducts,

nonsteroids

ATCVetCode:QM01AE91

5.1 Pharmacodynamicproperties

Carprofen(CPF),(

)-6-chloro- 

-methylcarbazole-2-aceticacid,isa

nonsteroidalanti-inflammatorydrug(NSAID)withanalgesicandanti-pyretic

properties.Itisaderivativeofphenylpropionicacidandamemberofthe

arylpropionicacidclassofNSAIDs.Asarepresentativeofthe2-

arylpropionicfamily,itcontainsachiralcenteratC

ofthepropionicmoiety

andtherefore,existsin2sterioisomericforms,the(+)-Sand(-)-R

enantiomers.

Themechanismofactionofcarprofenisunclear,therearetwoprincipal

theories.Oneproposesthatcarprofenisaselectiveinhibitorofthecyclo-

oxygenaseisoenzyme,COX-2.Thesecondhypothesisthatcarprofenisa

weakinhibitorofbothcyclo-oxygenaseisoforms,COX-1andCOX-2,and

thatitacts,atleastpartially,bysomeotherunknownmechanism.However

theS(+)enantiomerseemstoberesponsiblefortheselectiveCOX2

inhibitionofcarprofen.TheR(-)andS(+)enantiomersundergo

glucuronidationandtheS(+)enantiomerissubjectedtoenterohepatic

recycling.

Revised:November2012

AN:00800/2012

Page5of6

5.2 Pharmacokineticproperties

Followingsubcutaneousadministrationof4mgcarprofen/kg,peakplasma

concentrationsof12.6 μg/mlwereachievedinapproximately3hoursin

dogs.Bioavailabilityfollowingsubcutaneousadministrationisintherange

90-100%.Thevolumeofdistributionissmallwiththehighestdrug

concentrationsoccurringinplasma.Ratiosoftissuetoplasma

concentrationarelessthanonewhichisconsistentwithahighlevelof

bindingofcarprofentoplasmaproteins.Carprofenisprimarilyeliminatedby

biotransformationintheliverintoglucuronidemetabolites.70to80%of

metabolitesareeliminatedinfaecesand10-20%inurine.

Followingsinglesubcutaneousadministrationofcarprofenatadoserateof

4µg/kgbodyweighttodogs,thefollowingparameterswereobservedforthe

individualenantiomers(R-)and(S+)andtotalcarprofen:Cmax(R-)=6.51

µg/ml,Tmax(R-)=3.0hours,AUC(R-)=88.01µg/ml.hours,t

(R-)=9.098

hours;Cmax(S+)=6.15µg/ml,Tmax(S+)=3.125hours,AUC(S+)=80.01

µg/ml.hours,t

(S+)=8.139hours;Cmax(total)=12.6µg/ml,Tmax(total)=

3.031hours,AUC(total)=168.31µg/ml.hours,t

(total)=9.0hours.

Followingintravenousadministrationofcarprofentocatsahalf-life(t1/2)of

20.1±16.6hourswasobserved.Theeliminationhalf-lifeofcarprofenranged

from9to49hours.

6. PHARMACEUTICALPARTICULARS

6.1 ListofExcipient(s)

BenzylAlcohol

SodiumFormaldehydeSulphoxylate

L-Arginine

PoloxamerType188(LutrolF68)

WaterforInjections

6.2 Incompatibilities

Intheabsenceofcompatibilitystudiesthisveterinaryproductcannotbe

mixedwithotherproducts.

6.3 Shelf-Life

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:2years

Shelf-lifeafterfirstopeningtheimmediatepackaging:28days

Revised:November2012

AN:00800/2012

Page6of6

6.4 SpecialPrecautionsforStorage

Donotstoreabove25°C.

6.5 NatureandCompositionofImmediatePackaging

1x20ml,5x20ml,6x20ml,10x20mland12x20mlmultidoseamber

glass(Type1)vials,sealedwith20mmbromobutylbungsand20mm

aluminiumseals.

Notallpacksizesmaybemarketed.

6.6 SpecialPrecautionsfortheDisposalofUnusedVeterinaryMedicinal

ProductsorWasteMaterialsDerivedFromtheUseofSuchProducts,if

appropriate

Anyunusedveterinarymedicinalproductsorwastematerialsderivedfrom

suchveterinarymedicinalproductshouldbedisposedofinaccordancewith

localrequirements.

7. Nameorcorporatenameandaddressorregisteredplaceofbusinessof

theMarketingAuthorisationHolder

NorbrookLaboratoriesLimited

StationWorks

CamloughRoad

Newry

Co.Down

BT356JP

NorthernIreland

8. MARKETINGAUTHORISATIONNUMBER

Vm 02000/4268

9.DATEOFFIRSTAUTHORISATION

Date:02August2007

10.DATEOFREVISIONOFTEXT

Date:November2012

Approvedby: 15/11/2012

5-12-2018

Columbia River Natural Pet Foods Inc. Recalls Cow Pie Fresh Frozen Meats for Dogs and Cats Because of Possible <em>Listeria monocytogenes</em> Health Risk

Columbia River Natural Pet Foods Inc. Recalls Cow Pie Fresh Frozen Meats for Dogs and Cats Because of Possible <em>Listeria monocytogenes</em> Health Risk

Columbia River Natural Pet Foods of Vancouver, WA is voluntarily recalling 933 packages of Cow Pie fresh frozen meats for dogs and cats, produced in August 2017, because it has the potential to be contaminated with Listeria monocytogenes

FDA - U.S. Food and Drug Administration

5-12-2018

Public health risks associated with food‐borne parasites

Public health risks associated with food‐borne parasites

Published on: Tue, 04 Dec 2018 Parasites are important food‐borne pathogens. Their complex lifecycles, varied transmission routes, and prolonged periods between infection and symptoms mean that the public health burden and relative importance of different transmission routes are often difficult to assess. Furthermore, there are challenges in detection and diagnostics, and variations in reporting. A Europe‐focused ranking exercise, using multicriteria decision analysis, identified potentially food‐borne ...

Europe - EFSA - European Food Safety Authority Publications

30-11-2018

The European Union summary report on surveillance for the presence of transmissible spongiform encephalopathies (TSEs) in 2017

The European Union summary report on surveillance for the presence of transmissible spongiform encephalopathies (TSEs) in 2017

Published on: Thu, 29 Nov 2018 This report presents the results of surveillance on transmissible spongiform encephalopathies (TSEs) in bovine animals, sheep, goats, cervids and other animal species, as well as genotyping in sheep, carried out in 2017 in the European Union (EU) according to Regulation (EC) 999/2001, and in Iceland, Norway and Switzerland. In total, 1,312,714 cattle were tested by the 28 EU Member States (MSs) which is a decrease of 3% compared with 2016; 18,526 were tested by the three n...

Europe - EFSA - European Food Safety Authority Publications

26-11-2018

FDA Welcomes Grant Applications for Animal Drugs for Minor Uses and Minor Species

FDA Welcomes Grant Applications for Animal Drugs for Minor Uses and Minor Species

The U.S. Food and Drug Administration today announced an open period for applications for grants to support the development of new animal drugs intended to treat uncommon diseases (minor uses) in major species (horses, dogs, cats, cattle, pigs, turkeys and chickens) or to treat minor species.

FDA - U.S. Food and Drug Administration

22-11-2018

Safety and efficacy of Monteban® G100 (narasin) for ducks for fattening

Safety and efficacy of Monteban® G100 (narasin) for ducks for fattening

Published on: Wed, 21 Nov 2018 Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of Monteban® G100 for ducks. Monteban® G100, containing narasin, is intended for the prevention of coccidiosis in ducks for fattening at a dose range of 60–70 mg/kg of complete feed. Narasin from Monteban® G100 is safe for ducks for fattening at a level of 70 mg/kg complete feed...

Europe - EFSA - European Food Safety Authority Publications

16-11-2018

FDA Proposes Study with Intent of Eliminating Use of Dogs in Certain Types of Research

FDA Proposes Study with Intent of Eliminating Use of Dogs in Certain Types of Research

In keeping with the goals of reducing, replacing, and/or refining the use of animals in research, the U.S. Food and Drug Administration today released for public comment proposed research to validate an alternative approach for bioequivalence studies for certain animal drugs.

FDA - U.S. Food and Drug Administration

16-11-2018

Statement by FDA Commissioner Scott Gottlieb, M.D., on efforts to reduce animal testing through a study aimed at eliminating the use of dogs in certain trials

Statement by FDA Commissioner Scott Gottlieb, M.D., on efforts to reduce animal testing through a study aimed at eliminating the use of dogs in certain trials

Statement from FDA Commissioner Scott Gottlieb, M.D., on new efforts to reduce use of animals through a study aimed at eliminating the use of dogs in certain trials

FDA - U.S. Food and Drug Administration

15-11-2018

Safety and efficacy of Monimax® (monensin sodium and nicarbazin) for chickens for fattening and chickens reared for laying

Safety and efficacy of Monimax® (monensin sodium and nicarbazin) for chickens for fattening and chickens reared for laying

Published on: Wed, 14 Nov 2018 The coccidiostat Monimax® (monensin sodium and nicarbazin) is considered safe for chickens for fattening and chickens reared for laying at the highest use level of 50 mg monensin and 50 mg nicarbazin/kg complete feed. This conclusion is extended to chickens reared for laying. For both active substances, the metabolic pathways in the chicken are similar to those in the turkey and rat. Nicarbazin, when ingested, is rapidly split in its two components dinitrocarbanilide (DNC)...

Europe - EFSA - European Food Safety Authority Publications

31-10-2018

Safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos when used as a feed flavouring for all animal species

Safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos when used as a feed flavouring for all animal species

Published on: Tue, 30 Oct 2018 00:00:00 +0100 Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos (hop strobiles) when used as a sensory feed additive for all animal species. The additive is specified to containing 40% beta acids and less than 0.2% alpha acids. Known substances of conce...

Europe - EFSA - European Food Safety Authority Publications

17-10-2018

Lumpy skin disease: scientific and technical assistance on control and surveillance activities

Lumpy skin disease: scientific and technical assistance on control and surveillance activities

Published on: Tue, 16 Oct 2018 00:00:00 +0200 The duration of the vaccination campaign sufficient to eliminate lumpy skin disease (LSD) mainly depends on the vaccination effectiveness and coverage achieved. By using a spread epidemiological model, assuming a vaccination effectiveness of 65%, with 50% and 90% coverage, 3 and 4 years campaigns, respectively, are needed to eliminate LSD. When vaccination effectiveness is 80% to 95%, 2 years of vaccination at coverage of 90% is sufficient to eliminate LSD vir...

Europe - EFSA - European Food Safety Authority Publications

21-9-2018

FDA Animal Drug Safety Communication: FDA Reminds Veterinarians of the Differences Between Approved and Compounded Formulas of Transdermal Mirtazapine for the Management of Weight Loss in Cats

FDA Animal Drug Safety Communication: FDA Reminds Veterinarians of the Differences Between Approved and Compounded Formulas of Transdermal Mirtazapine for the Management of Weight Loss in Cats

CVM Update describing FDA Dear Veterinarian Letter about the differences between FDA-approved Mirataz (mirtazapine transdermal ointment), an animal drug with demonstrated safety and effectiveness to manage undesired weight loss in cats, and compounded formulations of transdermal mirtazapine.

FDA - U.S. Food and Drug Administration

20-9-2018

Siu & Sons Int'l Trading recalls Color Fantastik Assorted Rubber Animal Toys

Siu & Sons Int'l Trading recalls Color Fantastik Assorted Rubber Animal Toys

Health Canada's sampling and evaluation program has determined that the rubber animals do not meet the Canadian safety requirements for toys. The squeakers inside the rubber animals can be easily removed; these small parts pose a choking hazard to young children.

Health Canada

29-8-2018

Risk to human and animal health related to the presence of 4,15‐diacetoxyscirpenol in food and feed

Risk to human and animal health related to the presence of 4,15‐diacetoxyscirpenol in food and feed

Published on: Thu, 16 Aug 2018 00:00:00 +0200 4,15‐Diacetoxyscirpenol (DAS) is a mycotoxin primarily produced by Fusarium fungi and occurring predominantly in cereal grains. As requested by the European Commission, the EFSA Panel on Contaminants in the Food Chain (CONTAM) assessed the risk of DAS to human and animal health related to its presence in food and feed. Very limited information was available on toxicity and on toxicokinetics in experimental and farm animals. Due to the limitations in the avai...

Europe - EFSA - European Food Safety Authority Publications

29-6-2018

UPDATE: FDA Animal Drug Safety Communication: FDA continues to warn about risk of accidental overdosing of dogs with the noise aversion drug Sileo

UPDATE: FDA Animal Drug Safety Communication: FDA continues to warn about risk of accidental overdosing of dogs with the noise aversion drug Sileo

FDA is alerting dog owners and veterinarians about the risk of accidental overdose to dogs treated with the drug Sileo, a prescription gel that is given to dogs by mouth to treat noise aversion.

FDA - U.S. Food and Drug Administration

28-6-2018

FDA Releases Guidance to Help Animal Drug Sponsors with Antimicrobial Animal Drug Sales and Distribution Reporting Requirements

FDA Releases Guidance to Help Animal Drug Sponsors with Antimicrobial Animal Drug Sales and Distribution Reporting Requirements

FDA is releasing Guidance for Industry #252. This small entity compliance guide is intended to help small businesses comply with the Antimicrobial Animal Drug Sales and Distribution final rule.

FDA - U.S. Food and Drug Administration

7-6-2018

Prevent Heartworms in Dogs, Cats, and Ferrets Year-Round

Prevent Heartworms in Dogs, Cats, and Ferrets Year-Round

Heartworm disease can be fatal to pets, but it is also preventable. Learn more about the dangers of heartworm disease and the importance of year-round prevention.

FDA - U.S. Food and Drug Administration

31-5-2018

Apotex Corp. Issues Voluntary Nationwide Recall of Fluticasone Propionate Nasal Spray USP 50 mcg Per Spray 120 Metered Sprays Due to Potential for Small Glass Particles

Apotex Corp. Issues Voluntary Nationwide Recall of Fluticasone Propionate Nasal Spray USP 50 mcg Per Spray 120 Metered Sprays Due to Potential for Small Glass Particles

Apotex Corp. is voluntarily recalling one (1) lot of Fluticasone Propionate Nasal Spray, USP, 50 mcg per spray, 120 Metered Sprays, to the consumer level. The Fluticasone Propionate Nasal Spray USP 50 mcg per spray 120 Metered Sprays has been found to contain small glass particles. The glass particles could block the actuator and impact the functionality of the pump. The issue was discovered through a customer complaint.

FDA - U.S. Food and Drug Administration

24-5-2018

FDA Approves Semintra, the First FDA-approved Animal Drug for the Control of Systemic Hypertension in Cats

FDA Approves Semintra, the First FDA-approved Animal Drug for the Control of Systemic Hypertension in Cats

The FDA has approved Semintra (telmisartan oral solution), the first FDA-approved animal drug to control systemic hypertension in cats. Semintra is an oral solution administered either directly into the cat’s mouth or on top of a small amount of food.

FDA - U.S. Food and Drug Administration

23-5-2018

The FDA is Seeking Input on the Evaluation of Approaches to Demonstrate Effectiveness of Heartworm Preventatives for Dogs

The FDA is Seeking Input on the Evaluation of Approaches to Demonstrate Effectiveness of Heartworm Preventatives for Dogs

FDA’s CVM is evaluating the design of studies intended to support the standard of effectiveness for new animal drugs to prevent heartworm disease in dogs. The FDA is requesting public input on evaluating these products to assist in the potential development of alternative study designs.

FDA - U.S. Food and Drug Administration

14-5-2018

FDA Approves Mirataz, a New Animal Drug to Manage Undesired Weight Loss in Cats

FDA Approves Mirataz, a New Animal Drug to Manage Undesired Weight Loss in Cats

FDA has approved Mirataz (mirtazapine transdermal ointment), a new animal drug to manage undesired weight loss in cats. Mirataz is the first transdermal product to receive FDA approval for use in cats. FDA-approved drugs have been demonstrated to be safe and effective for their intended use.

FDA - U.S. Food and Drug Administration